QSAM Biosciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update
16 août 2022 08h00 HE
|
QSAM Biosciences Inc.
Progress Shown in Phase 1 Clinical Program Evaluating CycloSam® Radiopharmaceutical Drug Candidate for Treatment of Metastatic Bone Cancer AUSTIN, Texas, Aug. 16, 2022 (GLOBE NEWSWIRE) -- QSAM...